Compare Gilead Sciences, Inc. (GILD) vs D Wave Quantum Inc (QBTS) Price & Performance

Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.

Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.

D-Wave Quantum (QBTS) trades at $14.42, down 5.26% today, amid bearish technical signals and ongoing legal investigations. The company shows severe financial stress with a -2,001.59% net income margin and -$355M net loss in 2025, though it maintains a 64.19% gross margin. Revenue declined from $25M to $12M year-over-year, while cash flow turned negative in 2026. Despite 100% analyst buy ratings with a $34.38 consensus target, multiple law firms are investigating potential securities law violations.

The stock faces significant fundamental challenges with massive losses and declining revenue, offset by strong analyst optimism about quantum computing potential. Key risks include ongoing legal probes, cash burn acceleration, and competitive pressures in the emerging quantum sector. The current price sits 58% below analyst targets, creating potential upside if execution improves, but substantial operational turnaround is needed.